milestone payments
Twist Bioscience Signs $15M Royalty Purchase Agreement With Xoma Royalty
Xoma will pay $15 million in cash for rights to half of Twist's milestone and royalty payments from existing antibody discovery and biopharma collaborations.
Genuity Science, Ionis Pharmaceuticals Partner on Antisense Therapy Development
Genuity Science, formerly known as WuXi NextCode, will receive a combination of upfront, development milestone, and product royalty payments under the deal.
Amgen, Adaptive Biotechnologies Expand Partnership on NGS Blood Cancer Monitoring
The partners will use Adaptive's ClonoSeq assay to assess minimal residual disease in several of Amgen's hematology drug development programs.
Tempus, Genmab Collaborate on Cancer Biomarker Discovery
Tempus is eligible for milestone payments and royalties for any oncology therapeutics Genmab might develop based on their joint research projects.
Interpace Dx Reaches Deal to Restructure Debt
As part of the deal with an institutional investor, Interpace's royalty and milestone obligations will also be terminated.